Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Average Recommendation of “Hold” by Brokerages

Posted by Brian Himes on Sep 5th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) has been given a consensus recommendation of “Hold” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $4.00.

Several equities analysts have recently commented on HOWL shares. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th.

Get Our Latest Stock Report on Werewolf Therapeutics

Insiders Place Their Bets

In other Werewolf Therapeutics news, Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the transaction, the insider owned 303,719 shares in the company, valued at $106,301.65. The trade was a 57.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,824,647 shares of company stock valued at $670,677 over the last three months. 23.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in HOWL. Vontobel Holding Ltd. grew its position in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics during the 3rd quarter valued at about $304,000. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at about $409,000. Finally, Vanguard Group Inc. raised its stake in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Trading Up 2.4%

NASDAQ HOWL opened at $0.97 on Friday. Werewolf Therapeutics has a 1 year low of $0.27 and a 1 year high of $2.38. The firm has a market capitalization of $46.96 million, a P/E ratio of -1.27 and a beta of 0.51. The firm’s fifty day moving average price is $0.51 and its two-hundred day moving average price is $0.60.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.36. The company had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. On average, research analysts anticipate that Werewolf Therapeutics will post -0.89 EPS for the current fiscal year.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.